- The world has been given a reason to smile as WHO approved a new drug for Covid-19 treatment
- The global agency said dexamethasone can now be used to treat Covid-19 patients
- WHO made the announcement days after stopping solidarity trial of hydroxychloroquine
PAY ATTENTION: Click “See First” under the “Following” tab to see Legit.ng News on your Facebook News Feed
The World Health Organisation (WHO) has approved the use of dexamethasone to treat critically ill Covid-19 patients.
WHO made the announcement through its director-general, Tedros Ghebreyesus, on Monday, June 22, during a virtual briefing.
According to the global health agency, recent findings have shown that the "steroid dexamethasone has life-saving potential for critically ill COVID-19 patients.”
WHO DG, however, stated that the use is in its preliminary stage, adding that dexamethasone has shown huge benefit in the United Kingdom in what gives the world the reason to celebrate.
“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm.
“Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production,” the WHO DG said.
Meanwhile, there are 9,218,565 cases of Covid-19 in the world with the United States standing tall on the log with 2,388,225 cases.
474,966 deaths have been recorded globally, while 4,961,952 people have recovered from the virus.
Earlier, Legit.ng reported that as the world channels concentrated efforts against coronavirus crisis, WHO said it has finally halted hydroxychloroquine trial for Covid-19 treatment.
The global health agency made the declaration on Wednesday, June 17, in a tweet, saying the drug is not effective in treating the highly-ravaging infection.
If you have fever, it’s more likely due to malaria than COVID-19 - PTF coordinator says, begs private hospitals not to reject patients of other diseases
The decision came in barely three weeks after the United States Food and Drug Administration (FDA) stopped the drug use.
WHO said findings have shown that the anti-malaria drug does not reduce the mortality rate of coronavirus.
"The Solidarity Trial’s hydroxychloroquine arm is being stopped, on the basis of evidence showing it does not reduce mortality for hospitalised #COVID19 patients," WHO said in a tweet on Wednesday.
How Nigeria's Covid-19 cases rose from 7000 to over 20,000 in one month | Legit TV
Source: Legit.ng News